The Experts below are selected from a list of 1980 Experts worldwide ranked by ideXlab platform
Yutaka Osuga - One of the best experts on this subject based on the ideXlab platform.
-
A case of hemorrhagic shock occurred during Dienogest therapy for uterine adenomyosis.
The journal of obstetrics and gynaecology research, 2020Co-Authors: Masashi Takamura, Kaori Koga, Miyuki Harada, Yasushi Hirota, Tomoyuki Fujii, Yutaka OsugaAbstract:We present a case of hemorrhagic shock occurred during Dienogest therapy for uterine adenomyosis which necessitated an emergency hysterectomy. The patient was a 45-year-old woman with adenomyosis. Magnetic resonance imaging showed type I adenomyosis measuring 10 cm. She had a history of intimal thrombectomy of pulmonary embolism and had been receiving warfarin and aspirin until the onset of the hemorrhagic shock. Following 6-month of gonadotropin-releasing hormone analogue, Dienogest was commenced. Nine months after switching to Dienogest, the patient experienced a persistent abnormal uterine bleeding for 2 weeks, eventually causing a massive bleeding and was transferred to our emergency room. A diagnosis of hemorrhagic shock with a severe anemia (hemoglobin 3.6 g/dL) was made. Despite blood transfusion and warfarin antagonization, continuous bleeding ≥150 g/h was not controlled. Emergent hysterectomy was opted and enabled hemostasis. Although the number of patients with adenomyosis who can avoid surgery by Dienogest is increasing, care must be taken during Dienogest therapy, especially in patients with anticoagulants and after gonadotropin-releasing hormone analogue treatment. To prevent such a critical event, careful management including patient education should be carried out.
-
Dienogest suppresses cellular proliferation status of endometrial polyps and acts differently depending on the morphological type.
Women's health (London England), 2020Co-Authors: Kei Inaba, Kaori Koga, Miyuki Harada, Yasushi Hirota, Tomoyuki Fujii, Osamu Wada-hiraike, Yutaka OsugaAbstract:Administration of Dienogest prior to hysteroscopic polypectomy is empirically performed, but the physiological effects of Dienogest on endometrial polyps are unclear. We aimed to investigate the ef...
-
Dienogest reduces proliferation, NGF expression and nerve fiber density in human adenomyosis
European journal of obstetrics gynecology and reproductive biology, 2016Co-Authors: Arisa Takeuchi, Mariko Miyashita, Kaori Koga, Miyuki Harada, Tetsuya Hirata, Yasushi Hirota, Tomoyuki Fujii, Tomoko Makabe, Fusako Sue, Yutaka OsugaAbstract:Abstract Objectives To evaluate the in vivo effect of Dienogest on proliferation, apoptosis, aromatase expression, vascular density, nerve growth factor (NGF) expression and nerve fiber density in human adenomyosis tissue. Study design Twelve women who underwent hysterectomy for adenomyosis were enrolled. Six patients received Dienogest treatment prior to hysterectomy (Dienogest group), and age-matched six patients who had not received any hormonal treatment for ≥3 months before surgery (control group). Cell proliferation, vascular and nerve fiber density in adenomyosis tissue were evaluated by staining for Ki67, von Willebrand factor and PGP9.5, respectively. Apoptosis was detected using the TUNEL assay. The expression aromatase and NGF were evaluated by staining for corresponding antibodies. Results The proportion of Ki67 positive epithelial cells was significantly lower in samples from Dienogest-treated patients in comparison with controls ( p p = 0.07). The intensity of NGF expression and the density of nerve fibers were significantly lower in the Dienogest group compared with controls ( p Conclusion This study demonstrates that adenomyosis, taken from patients treated with Dienogest, shows remarkable histological features, such as reductions in proliferation, NGF expression and nerve fiber density. These findings indicate the impact of Dienogest on local histological events, and explains its therapeutic effect on adenomyosis.
-
Dienogest reduces proliferation aromatase expression and angiogenesis and increases apoptosis in human endometriosis
Gynecological Endocrinology, 2014Co-Authors: Mariko Miyashita, Kaori Koga, Masashi Takamura, Gentaro Izumi, Miwako Nagai, Miyuki Harada, Tetsuya Hirata, Yasushi Hirota, Tomoyuki Fujii, Yutaka OsugaAbstract:AbstractDienogest is a novel progestin that is highly selective for progesterone receptors and inhibits endometriosis. However, it remains unknown how the administration of Dienogest to patients with endometriosis impacts on their lesion tissues. The aim of this study was to evaluate the in vivo effect of Dienogest on endometriosis tissue. We collected endometrioma tissues from patients treated with Dienogest (N = 7) or not treated (N = 11, controls). Cell proliferation, aromatase expression and blood vessel density were evaluated by staining for Ki67, aromatase and the von Willebrand factor, respectively. Apoptosis was detected using the TUNEL assay. The proportion of Ki67 and aromatase positive epithelial cells was significantly lower in the Dienogest group than in controls (p < 0.05, respectively). The number of TUNEL positive cells was significantly higher in the Dienogest group (p < 0.05). The density of blood vessels in endometrioma was marginally lower in the Dienogest group compared with controls ...
-
Efficacy of Dienogest in the treatment of symptomatic adenomyosis: a pilot study
Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, 2014Co-Authors: Tetsuya Hirata, Kaori Koga, Masashi Takamura, Gentaro Izumi, Miyuki Harada, Yasushi Hirota, Tomoyuki Fujii, Akari Nakazawa, Ako Saito, Yutaka OsugaAbstract:AbstractAdenomyosis is a common disorder in premenopausal women that causes dysmenorrhea, pelvic pain and menorrhagia. Considering that adenomyosis is an estrogen-dependent disease, the medical treatment is based on this hormone. Effective and well-tolerated medical treatments for symptomatic adenomyosis are needed. Dienogest, an oral progestin, has been extensively investigated in the treatment of endometriosis. In this report, we present the results on the efficacy and safety of Dienogest in the treatment of symptomatic adenomyosis. Seventeen patients with symptomatic adenomyosis were included in this study, of which 15 continued Dienogest for up to 24 weeks. Dienogest significantly reduced adenomyosis-associated pelvic pain as well as serum CA-125 and CA19-9 levels. It also demonstrated a modest suppression of estradiol (>50 pg/ mL), which is consistent with the findings of other reports. During treatment, five patients experienced worsening anemia because of metrorrhagia, which is the most frequent ad...
Chi Chiu Wang - One of the best experts on this subject based on the ideXlab platform.
-
Efficacy, safety and recurrence of new progestins and selective progesterone receptor modulator for the treatment of endometriosis: a comparison study in mice
Reproductive Biology and Endocrinology, 2018Co-Authors: Bo Liang, Ling Wu, Hui Xu, Chun Wai Cheung, Wen Ying Fung, Sze Wai Wong, Chi Chiu WangAbstract:Background Current medical treatments for endometriosis are very limited. Progestin and selective progesterone receptor modulators (SPRM) are developed but their efficacy, safety, mechanism and recurrence in endometriosis are not fully studied. Methods In order to compare therapeutic, side effects and therapeutic actions of Esmya, Duphaston and Dienogest in endometriosis. Experimental endometriosis was induced by either intraperitoneal or subcutaneous mouse endometrium transplantation. Lesion size, weight and histology at the end of intervention were compared. Expression of related markers in the endometriotic lesions were examined. Body, uterus and ovary weights, endometrial glands and thickness (ETI), and follicle count were measured. For recurrent study, lesion growth before and after intervention was monitored. Results After Esmya, Duphaston, Dienogest treatment, lesion size and weight were significantly decreased. Proliferation Pcna expression was significantly decreased in all groups, but proliferation cells were significantly decreased only in Duphaston group. Apoptosis Mapk1 expression and TUNEL-positive cells were significantly increased in Duphaston group. Adhesion Mmp2 and Itgavβ3 expression were significantly increased in Esmya group. Plau, Hif1α and Vegfa expression, peritoneal fluid PGE2 levels, and ERα and ERβ expression were not affected; while PR expression was significantly lower in all groups. Endometrial gland count in uterus was significantly increased in Dienogest group, ETI was significantly decreased in Duphaston group, and AFC were significantly increased in Esmya group. Upon treatment cessation, lesion growth rebound quickly in Dienogest and Duphaston groups, but slowly in Esmya group. Conclusion Esmya, Duphaston and Dienogest are effective anti-endometriosis drugs targeting proliferation, apoptosis and adhesion. Esmya, Duphaston and Dienogest are all well tolerable, although endometrial glandular hyperplasia was found in Dienogest, endometrial atrophy in Duphaston, follicle accumulation in Esmya.
-
efficacy safety and recurrence of new progestins and selective progesterone receptor modulator for the treatment of endometriosis a comparison study in mice
Reproductive Biology and Endocrinology, 2018Co-Authors: Bo Liang, Chun Wai Cheung, Wen Ying Fung, Sze Wai Wong, Chi Chiu WangAbstract:Current medical treatments for endometriosis are very limited. Progestin and selective progesterone receptor modulators (SPRM) are developed but their efficacy, safety, mechanism and recurrence in endometriosis are not fully studied. In order to compare therapeutic, side effects and therapeutic actions of Esmya, Duphaston and Dienogest in endometriosis. Experimental endometriosis was induced by either intraperitoneal or subcutaneous mouse endometrium transplantation. Lesion size, weight and histology at the end of intervention were compared. Expression of related markers in the endometriotic lesions were examined. Body, uterus and ovary weights, endometrial glands and thickness (ETI), and follicle count were measured. For recurrent study, lesion growth before and after intervention was monitored. After Esmya, Duphaston, Dienogest treatment, lesion size and weight were significantly decreased. Proliferation Pcna expression was significantly decreased in all groups, but proliferation cells were significantly decreased only in Duphaston group. Apoptosis Mapk1 expression and TUNEL-positive cells were significantly increased in Duphaston group. Adhesion Mmp2 and Itgavβ3 expression were significantly increased in Esmya group. Plau, Hif1α and Vegfa expression, peritoneal fluid PGE2 levels, and ERα and ERβ expression were not affected; while PR expression was significantly lower in all groups. Endometrial gland count in uterus was significantly increased in Dienogest group, ETI was significantly decreased in Duphaston group, and AFC were significantly increased in Esmya group. Upon treatment cessation, lesion growth rebound quickly in Dienogest and Duphaston groups, but slowly in Esmya group. Esmya, Duphaston and Dienogest are effective anti-endometriosis drugs targeting proliferation, apoptosis and adhesion. Esmya, Duphaston and Dienogest are all well tolerable, although endometrial glandular hyperplasia was found in Dienogest, endometrial atrophy in Duphaston, follicle accumulation in Esmya.
Tetsuya Hirata - One of the best experts on this subject based on the ideXlab platform.
-
Long-term Dienogest administration in patients with symptomatic adenomyosis.
The journal of obstetrics and gynaecology research, 2018Co-Authors: Kazuaki Neriishi, Kaori Koga, Gentaro Izumi, Miyuki Harada, Tetsuya Hirata, Shinya Fukuda, Akari Nakazawa, Naoko Yamamoto, Yaushi Hirota, Osamu Wada-hiraikeAbstract:Aim Adenomyosis is a common gynecological disorder that causes dysmenorrhea, hypermenorrhea and metrorrhagia. Previously, we reported that 24 weeks of Dienogest treatment is highly effective for pain in symptomatic adenomyosis. Up to present, there is no report that describes treatment of adenomyosis with long-term Dienogest administration for more than 2 years. In this retrospective cohort study, we investigated the course of long-term Dienogest treatment in patients with symptomatic adenomyosis. Methods This is a retrospective cohort study. Dienogest was continuously administered at a dose of 2 mg daily for patients with symptomatic adenomyosis. The outcome of long-term administration of Dienogest was investigated, and the characteristics of patients were compared between discontinued cases and long-term administration cases. Results Two patients were excluded from this study because of transfer to another hospital or discontinuation due to infertility treatment. Twelve of 18 patients (66.7%) received Dienogest until menopause or for a period of >80 months. Four cases (22.2%) discontinued Dienogest treatment because of severe metrorrhagia. In the discontinued cases because of severe metrorrhagia, the pain score for dysmenorrhea and serum CA125 level at baseline significantly elevated, and the hemoglobin level at baseline and the frequency of type 2 adenomyosis significantly decreased, compared to those with long-term use. Moreover, long-term Dienogest use did not decrease the serum estradiol level. Conclusion Our report suggests that Dienogest is tolerable for long-term use until menopause and can be an alternative treatment option in some patients, especially those with type 2 adenomyosis, to avoid hysterectomy.
-
Dienogest reduces proliferation, NGF expression and nerve fiber density in human adenomyosis
European journal of obstetrics gynecology and reproductive biology, 2016Co-Authors: Arisa Takeuchi, Mariko Miyashita, Kaori Koga, Miyuki Harada, Tetsuya Hirata, Yasushi Hirota, Tomoyuki Fujii, Tomoko Makabe, Fusako Sue, Yutaka OsugaAbstract:Abstract Objectives To evaluate the in vivo effect of Dienogest on proliferation, apoptosis, aromatase expression, vascular density, nerve growth factor (NGF) expression and nerve fiber density in human adenomyosis tissue. Study design Twelve women who underwent hysterectomy for adenomyosis were enrolled. Six patients received Dienogest treatment prior to hysterectomy (Dienogest group), and age-matched six patients who had not received any hormonal treatment for ≥3 months before surgery (control group). Cell proliferation, vascular and nerve fiber density in adenomyosis tissue were evaluated by staining for Ki67, von Willebrand factor and PGP9.5, respectively. Apoptosis was detected using the TUNEL assay. The expression aromatase and NGF were evaluated by staining for corresponding antibodies. Results The proportion of Ki67 positive epithelial cells was significantly lower in samples from Dienogest-treated patients in comparison with controls ( p p = 0.07). The intensity of NGF expression and the density of nerve fibers were significantly lower in the Dienogest group compared with controls ( p Conclusion This study demonstrates that adenomyosis, taken from patients treated with Dienogest, shows remarkable histological features, such as reductions in proliferation, NGF expression and nerve fiber density. These findings indicate the impact of Dienogest on local histological events, and explains its therapeutic effect on adenomyosis.
-
Dienogest reduces proliferation aromatase expression and angiogenesis and increases apoptosis in human endometriosis
Gynecological Endocrinology, 2014Co-Authors: Mariko Miyashita, Kaori Koga, Masashi Takamura, Gentaro Izumi, Miwako Nagai, Miyuki Harada, Tetsuya Hirata, Yasushi Hirota, Tomoyuki Fujii, Yutaka OsugaAbstract:AbstractDienogest is a novel progestin that is highly selective for progesterone receptors and inhibits endometriosis. However, it remains unknown how the administration of Dienogest to patients with endometriosis impacts on their lesion tissues. The aim of this study was to evaluate the in vivo effect of Dienogest on endometriosis tissue. We collected endometrioma tissues from patients treated with Dienogest (N = 7) or not treated (N = 11, controls). Cell proliferation, aromatase expression and blood vessel density were evaluated by staining for Ki67, aromatase and the von Willebrand factor, respectively. Apoptosis was detected using the TUNEL assay. The proportion of Ki67 and aromatase positive epithelial cells was significantly lower in the Dienogest group than in controls (p < 0.05, respectively). The number of TUNEL positive cells was significantly higher in the Dienogest group (p < 0.05). The density of blood vessels in endometrioma was marginally lower in the Dienogest group compared with controls ...
-
Efficacy of Dienogest in the treatment of symptomatic adenomyosis: a pilot study
Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, 2014Co-Authors: Tetsuya Hirata, Kaori Koga, Masashi Takamura, Gentaro Izumi, Miyuki Harada, Yasushi Hirota, Tomoyuki Fujii, Akari Nakazawa, Ako Saito, Yutaka OsugaAbstract:AbstractAdenomyosis is a common disorder in premenopausal women that causes dysmenorrhea, pelvic pain and menorrhagia. Considering that adenomyosis is an estrogen-dependent disease, the medical treatment is based on this hormone. Effective and well-tolerated medical treatments for symptomatic adenomyosis are needed. Dienogest, an oral progestin, has been extensively investigated in the treatment of endometriosis. In this report, we present the results on the efficacy and safety of Dienogest in the treatment of symptomatic adenomyosis. Seventeen patients with symptomatic adenomyosis were included in this study, of which 15 continued Dienogest for up to 24 weeks. Dienogest significantly reduced adenomyosis-associated pelvic pain as well as serum CA-125 and CA19-9 levels. It also demonstrated a modest suppression of estradiol (>50 pg/ mL), which is consistent with the findings of other reports. During treatment, five patients experienced worsening anemia because of metrorrhagia, which is the most frequent ad...
-
Dienogest reduces proliferation, aromatase expression and angiogenesis, and increases apoptosis in human endometriosis
Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, 2014Co-Authors: Mariko Miyashita, Kaori Koga, Masashi Takamura, Gentaro Izumi, Miwako Nagai, Miyuki Harada, Tetsuya Hirata, Yasushi Hirota, Tomoyuki Fujii, Yutaka OsugaAbstract:AbstractDienogest is a novel progestin that is highly selective for progesterone receptors and inhibits endometriosis. However, it remains unknown how the administration of Dienogest to patients with endometriosis impacts on their lesion tissues. The aim of this study was to evaluate the in vivo effect of Dienogest on endometriosis tissue. We collected endometrioma tissues from patients treated with Dienogest (N = 7) or not treated (N = 11, controls). Cell proliferation, aromatase expression and blood vessel density were evaluated by staining for Ki67, aromatase and the von Willebrand factor, respectively. Apoptosis was detected using the TUNEL assay. The proportion of Ki67 and aromatase positive epithelial cells was significantly lower in the Dienogest group than in controls (p
Yuji Taketani - One of the best experts on this subject based on the ideXlab platform.
-
Dienogest inhibits brdu uptake with g0 g1 arrest in cultured endometriotic stromal cells
Fertility and Sterility, 2008Co-Authors: Yutaka Osuga, Tetsuya Hirata, Yasushi Hirota, Chieko Morimoto, Tetsu Yano, Yuji TaketaniAbstract:Objective To investigate the effect of Dienogest on the proliferation of endometriotic stromal cells. Design Comparative and laboratory study. Setting University of Tokyo Hospital. Patient(s) Endometriotic stromal cells were isolated and cultured from ovarian endometriomas of patients undergoing surgery. Intervention(s) Dienogest was added to the cultured endometriotic stromal cells. Main Outcome Measure(s) 5-Bromo-2′-deoxyuridine (BrdU) incorporation into DNA of the endometriotic stromal cells was measured by ELISA. Cell cycle analysis of the cultured endometriotic stromal cells was performed by flow cytometry. Result(s) Dienogest at concentration of 10 -7 M and 10 -6 M significantly inhibited BrdU incorporation into DNA at 24 and 48 hours. Dienogest significantly increased the cells in G 0 /G 1 phase and reduced the cells in S phase and G 2 /M phase in 24 and 48 hours. Conclusion(s) The present study indicates that Dienogest can inhibit the proliferation of the endometriotic stromal cells with G 0 /G 1 arrest, suggesting a possible direct effect of Dienogest in the treatment of endometriosis.
-
Dienogest inhibits BrdU uptake with G0/G1 arrest in cultured endometriotic stromal cells
Fertility and Sterility, 2008Co-Authors: Yutaka Osuga, Tetsuya Hirata, Yasushi Hirota, Chieko Morimoto, Tetsu Yano, Yuji TaketaniAbstract:Objective To investigate the effect of Dienogest on the proliferation of endometriotic stromal cells. Design Comparative and laboratory study. Setting University of Tokyo Hospital. Patient(s) Endometriotic stromal cells were isolated and cultured from ovarian endometriomas of patients undergoing surgery. Intervention(s) Dienogest was added to the cultured endometriotic stromal cells. Main Outcome Measure(s) 5-Bromo-2′-deoxyuridine (BrdU) incorporation into DNA of the endometriotic stromal cells was measured by ELISA. Cell cycle analysis of the cultured endometriotic stromal cells was performed by flow cytometry. Result(s) Dienogest at concentration of 10 -7 M and 10 -6 M significantly inhibited BrdU incorporation into DNA at 24 and 48 hours. Dienogest significantly increased the cells in G 0 /G 1 phase and reduced the cells in S phase and G 2 /M phase in 24 and 48 hours. Conclusion(s) The present study indicates that Dienogest can inhibit the proliferation of the endometriotic stromal cells with G 0 /G 1 arrest, suggesting a possible direct effect of Dienogest in the treatment of endometriosis.
-
Dienogest inhibits BrdU uptake with G0/G1 arrest in cultured endometriotic stromal cells.
Fertility and sterility, 2007Co-Authors: Yutaka Osuga, Tetsuya Hirata, Yasushi Hirota, Chieko Morimoto, Tetsu Yano, Yuji TaketaniAbstract:To investigate the effect of Dienogest on the proliferation of endometriotic stromal cells. Comparative and laboratory study. University of Tokyo Hospital. Endometriotic stromal cells were isolated and cultured from ovarian endometriomas of patients undergoing surgery. Dienogest was added to the cultured endometriotic stromal cells. 5-Bromo-2'-deoxyuridine (BrdU) incorporation into DNA of the endometriotic stromal cells was measured by ELISA. Cell cycle analysis of the cultured endometriotic stromal cells was performed by flow cytometry. Dienogest at concentration of 10(-7) M and 10(-6) M significantly inhibited BrdU incorporation into DNA at 24 and 48 hours. Dienogest significantly increased the cells in G0/G1 phase and reduced the cells in S phase and G2/M phase in 24 and 48 hours. The present study indicates that Dienogest can inhibit the proliferation of the endometriotic stromal cells with G0/G1 arrest, suggesting a possible direct effect of Dienogest in the treatment of endometriosis.
Bo Liang - One of the best experts on this subject based on the ideXlab platform.
-
Efficacy, safety and recurrence of new progestins and selective progesterone receptor modulator for the treatment of endometriosis: a comparison study in mice
Reproductive Biology and Endocrinology, 2018Co-Authors: Bo Liang, Ling Wu, Hui Xu, Chun Wai Cheung, Wen Ying Fung, Sze Wai Wong, Chi Chiu WangAbstract:Background Current medical treatments for endometriosis are very limited. Progestin and selective progesterone receptor modulators (SPRM) are developed but their efficacy, safety, mechanism and recurrence in endometriosis are not fully studied. Methods In order to compare therapeutic, side effects and therapeutic actions of Esmya, Duphaston and Dienogest in endometriosis. Experimental endometriosis was induced by either intraperitoneal or subcutaneous mouse endometrium transplantation. Lesion size, weight and histology at the end of intervention were compared. Expression of related markers in the endometriotic lesions were examined. Body, uterus and ovary weights, endometrial glands and thickness (ETI), and follicle count were measured. For recurrent study, lesion growth before and after intervention was monitored. Results After Esmya, Duphaston, Dienogest treatment, lesion size and weight were significantly decreased. Proliferation Pcna expression was significantly decreased in all groups, but proliferation cells were significantly decreased only in Duphaston group. Apoptosis Mapk1 expression and TUNEL-positive cells were significantly increased in Duphaston group. Adhesion Mmp2 and Itgavβ3 expression were significantly increased in Esmya group. Plau, Hif1α and Vegfa expression, peritoneal fluid PGE2 levels, and ERα and ERβ expression were not affected; while PR expression was significantly lower in all groups. Endometrial gland count in uterus was significantly increased in Dienogest group, ETI was significantly decreased in Duphaston group, and AFC were significantly increased in Esmya group. Upon treatment cessation, lesion growth rebound quickly in Dienogest and Duphaston groups, but slowly in Esmya group. Conclusion Esmya, Duphaston and Dienogest are effective anti-endometriosis drugs targeting proliferation, apoptosis and adhesion. Esmya, Duphaston and Dienogest are all well tolerable, although endometrial glandular hyperplasia was found in Dienogest, endometrial atrophy in Duphaston, follicle accumulation in Esmya.
-
efficacy safety and recurrence of new progestins and selective progesterone receptor modulator for the treatment of endometriosis a comparison study in mice
Reproductive Biology and Endocrinology, 2018Co-Authors: Bo Liang, Chun Wai Cheung, Wen Ying Fung, Sze Wai Wong, Chi Chiu WangAbstract:Current medical treatments for endometriosis are very limited. Progestin and selective progesterone receptor modulators (SPRM) are developed but their efficacy, safety, mechanism and recurrence in endometriosis are not fully studied. In order to compare therapeutic, side effects and therapeutic actions of Esmya, Duphaston and Dienogest in endometriosis. Experimental endometriosis was induced by either intraperitoneal or subcutaneous mouse endometrium transplantation. Lesion size, weight and histology at the end of intervention were compared. Expression of related markers in the endometriotic lesions were examined. Body, uterus and ovary weights, endometrial glands and thickness (ETI), and follicle count were measured. For recurrent study, lesion growth before and after intervention was monitored. After Esmya, Duphaston, Dienogest treatment, lesion size and weight were significantly decreased. Proliferation Pcna expression was significantly decreased in all groups, but proliferation cells were significantly decreased only in Duphaston group. Apoptosis Mapk1 expression and TUNEL-positive cells were significantly increased in Duphaston group. Adhesion Mmp2 and Itgavβ3 expression were significantly increased in Esmya group. Plau, Hif1α and Vegfa expression, peritoneal fluid PGE2 levels, and ERα and ERβ expression were not affected; while PR expression was significantly lower in all groups. Endometrial gland count in uterus was significantly increased in Dienogest group, ETI was significantly decreased in Duphaston group, and AFC were significantly increased in Esmya group. Upon treatment cessation, lesion growth rebound quickly in Dienogest and Duphaston groups, but slowly in Esmya group. Esmya, Duphaston and Dienogest are effective anti-endometriosis drugs targeting proliferation, apoptosis and adhesion. Esmya, Duphaston and Dienogest are all well tolerable, although endometrial glandular hyperplasia was found in Dienogest, endometrial atrophy in Duphaston, follicle accumulation in Esmya.